drugset / Trial / NCT05856331
Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase 2 study to compare SAR447537 (INBRX-101) to plasma derived A1PI therapy in adults with AATD emphysema
Timeline
- Start
- 2023-10-12
- Primary completion
- 2025-08-06
- Completion
- 2025-08-06
Outcome
Met primary endpoint
release “NCT05856331 ) showed that efdoralprin alfa (SAR447537, formerly known as INBRX-101), met all primary and key secondary endpoints” sanofi.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alpha 1-Antitrypsin | Protein / enzyme biologic | 60 mg/kg | Intravenous |
| Subject | SAR447537 | Protein / enzyme biologic | — | Intravenous |